CSPC Pharmaceutical Group’s Stock Price Drops to 4.71 HKD, Witnessing a 2.69% Decline: What’s Next?

CSPC Pharmaceutical Group (1093)

4.71 HKD -0.13 (-2.69%) Volume: 115.8M

CSPC Pharmaceutical Group’s stock price stands at 4.71 HKD, experiencing a trading session drop of -2.69%, with a high trading volume of 115.8M. The stock has seen a significant downtrend YTD, with a percentage change of -35.12%, indicating a challenging market performance.

Latest developments on CSPC Pharmaceutical Group

Today, CSPC Pharmaceutical Group‘s stock price experienced fluctuations following key events in the pharmaceutical industry. Ipsen filed a lawsuit against CSPC Pharma to prevent the launch of a branded rival to a cancer drug, causing uncertainty in the market. Additionally, M Stanley reduced its target price for CSPC Pharma to $6.9, citing future challenges ahead. Jefferies also lowered its target price to $6.3, despite maintaining a Buy rating. These developments have contributed to the stock price movements of CSPC Pharmaceutical Group today.

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, like Tina Banerjee, are bullish on CSPC Pharmaceutical Group (1093 HK) as they see deep value and high dividend yield potential. According to Banerjee’s research report, CSPC Pharmaceutical reported steady growth in finished drugs in 2023, with new products such as Mingfule, Yilouda, and Anfulike driving sales ramp-up. The company plans to launch 50 innovative drugs in the next five years, providing continuous momentum for growth. Despite trading at a P/E of 11.3x, the lowest in the last five years, and being cheaper than peers, CSPC Pharmaceutical’s dividend yield remains attractive at 4%+.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group has a positive long-term outlook. With high scores in Value, Dividend, Growth, and Resilience, the company is positioned well for future success. The strong performance in these areas indicates that CSPC Pharmaceutical Group is a solid investment option for those looking for stability and potential growth in the pharmaceutical industry.

CSPC Pharmaceutical Group Limited, known for its manufacturing and sale of pharmaceutical products such as vitamin C, antibiotics, and generic drugs, is also involved in the development of innovative drugs and antibiotics. With a strong focus on dividends and growth, coupled with its resilience in the market, CSPC Pharmaceutical Group is set to continue its trajectory of success in the coming years.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma